T lymphocyte activation via major histocompatibility complex class I and class II pathways

T lymphocyte activation via major histocompatibility complex (MHC) class I and II pathways refers to the fundamental immunological processes by which **T cells recognize antigens presented on the surface of other cells**. This recognition is mediated through two main classes of MHC molecules: **MHC class I** molecules are expressed on all nucleated cells and present endogenous peptides—typically derived from intracellular proteins—to **cytotoxic CD8+ T cells**, leading to their activation. This is crucial for defense against viruses and some tumors[1][2][6]. **MHC class II** molecules are primarily found on professional antigen-presenting cells such as dendritic cells, macrophages, and B cells. They present exogenous peptides—derived from extracellular pathogens—to **helper CD4+ T cells**, which then coordinate broader immune responses including cytokine secretion and stimulation of other immune effector functions[1][2]. The process involves several steps: * Antigen processing within the presenting cell. * Loading of peptide fragments onto either MHC-I or MHC-II in specialized cellular compartments. * Presentation at the cell surface for surveillance by circulating naïve or memory T lymphocytes. * Engagement with clonotypic **T cell receptors (TCRs)** triggers intracellular signaling cascades that result in gene transcription changes driving proliferation, differentiation, survival, cytokine production, and effector function[3][5][7]. * Full activation requires additional co-stimulatory signals provided by accessory receptors such as CD28 interacting with B7 family ligands on antigen-presenting cells[3][5]. This system underpins adaptive immunity but is also implicated in pathological conditions when dysregulated—including autoimmunity if self-antigens are presented aberrantly. Note: "T lymphocyte activation via MHC class I and II pathways" describes an essential *process*, not a single molecular entity; thus it does *not* fit standard definitions for therapeutic targets like receptors or enzymes. Drugs may target individual components within these pathways but do not directly interact with "the pathway" itself. There is something incorrect about this entry as a drug target because it refers to an entire biological mechanism rather than a specific molecule suitable for direct pharmacologic modulation.

Other names

T cell activation via MHC-I and MHC-IIT lymphocyte activation by antigen presentationAntigen-dependent T cell activation pathways